#USA #Rockville #Alzheimer's #TrilliumBiO #T-NeuroDx

Strategic Collaboration to Enhance Alzheimer's Diagnostics

In a groundbreaking move aimed at revolutionizing the detection of Alzheimer's disease, TrilliumBiO, a prominent figure in the realm of biomarker discovery and precision diagnostics, has teamed up with T-NeuroDx, a company that is pioneering advancements in neurodegenerative disease diagnostics. This partnership is designed to expedite the development and commercialization of blood-based biomarkers, offering non-invasive diagnostic tools for early detection of Alzheimer's disease.

The collaboration leverages TrilliumBiO's extensive experience in developing diagnostic assays and clinical validation and T-NeuroDx's profound understanding of the pathology of Alzheimer's disease. By merging their strengths, the two companies are set to co-develop and validate blood-based biomarkers that will enable earlier diagnosis, tackling a critical challenge in neurodegenerative care.

Laura Vivian, CEO of TrilliumBiO, expressed pride in the alliance with T-NeuroDx, stating, "We are proud to partner with T-NeuroDx to bring more accessible, non-invasive diagnostics to patients and providers. By combining our diagnostic development capabilities with their cutting-edge biomarker science, we aim to help shift Alzheimer's detection from late-stage confirmation to early, actionable insight."

Blood-based biomarkers present a transformative approach in the landscape of Alzheimer's disease diagnostics. The strategic partnership will focus on commercializing T-Neuro's technology as a Lab Developed Test (LDT) and exploring investigational biomarkers that can signal Alzheimer's disease earlier in its progression. This advancement is vital for supporting timely diagnosis and effective disease management.

Michael Reed, Ph.D., Chief Development Officer of T-NeuroDx, highlighted the importance of the partnership in enhancing early detection efforts, saying, "This partnership accelerates our core mission to advance the early detection of Alzheimer's disease. TrilliumBiO's commitment to providing cutting-edge diagnostic solutions to underserved communities aligns perfectly with our own and strengthens our combined effort to revolutionize early-stage Alzheimer's care."

The initiative plans to conduct clinical studies across diverse demographics, aiming to support regulatory submissions and bring clinically validated blood tests for Alzheimer's disease to market in the near future.

About TrilliumBiO

TrilliumBiO specializes in the discovery of biomarkers and collaborates with healthcare innovators to develop and commercialize novel diagnostic tests. With proven expertise in translating clinical insights into market-ready solutions, they provide validated diagnostics for complex medical challenges. More information can be found on their website, TrilliumBiO.com.

About T-NeuroDx

T-NeuroDx is at the forefront of neurodegenerative disease research, focusing on early-stage diagnostic solutions for Alzheimer's disease. The company is developing an innovative biomarker capable of identifying Alzheimer's in its nascent stages by detecting dysfunctional T cells, which play a role in the disease's progression. Their work promises to reshape Alzheimer's drug development and patient care. For additional details, visit TNeuroDx.com.

This collaboration signals a significant stride forward in addressing the challenges associated with Alzheimer's diagnosis, emphasizing the importance of early detection and treatment possibilities. As the two companies embark on this venture, stakeholders in the medical and research communities eagerly await the advancements that will emerge from their joint efforts.